PATENT

Docket No.: S63.2B-9826-US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dachuan Yang, Liquang Tang and Dixie Lang

Application No.: 09/

09/908070 July 18, 2001

Filed: For:

FLUORESCENT DYED LUBRICANT FOR

MEDICAL DEVICES

Examiner:

Jessica Baxter

Group Art Unit:

1762

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Listed below or on an attached form listing the cited references and/or a copy of a PTO-892 form is information known to applicant(s). A copy of each listed publication, U.S. patent, foreign patent and U.S. patent application is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98, except that U.S. applications from which priority is claimed under 35 U.S.C. §120, and documents cited in such priority applications, may be omitted from the enclosures pursuant to 37 C.F.R. 1.98(d). Applicant's submission of copies of U.S. applications does not constitute a waiver of the confidentiality of such applications. As such, Applicant requests that any copies of unpublished US applications submitted herewith be excluded from the file wrapper pursuant to 37 C.F.R. §1.14.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If the form listing the cited references or PTO-892 from a prior application is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

Application No. 09/90807009/908070 Page 2 S63.2B-9826-US01 Supplemental Information Disclosure Statement Attorney Docket No S63.2-9826-US01.

Applications that are listed on the accompanying form listing the cited references as related by priority are related by priority claim under 35 USC §120. Pursuant to 37 CFR §1.98(d), no copies of cited art in a previous application(s) to which priority was claimed need be submitted. Applicant is providing copies of the form listing the cited references and/or 892 forms from these cases.

Χ	I. This states	ment qualifies as a no-fee Information Disclosure Statement under 37 C.F.R.						
		e because to the knowledge of the undersigned attorney it is being filed						
	all that a p ply							
`	(1)	within 3 months of the filing date of the application (other than a CPA); or						
	(2)	within 3 months of entry of the national stage; or						
	(3)	before the mailing of a first Office Action on the merits;						
	<u>X</u> (4)	before the mailing of a first Office Action after the filing of a request for						
		continued examination (RCE) under §1.114;						
	(5)	as part of a continued prosecution application (CPA); or						
	(6)	during the period of a suspension of action for a CPA under 37 C.F.R.						
		§1.103(b).						
	II. This stat	ement is believed to require a fee or the submission of a certification under						
	37 C.F.R. §1.97 (c) or otherwise. If this statement is being filed after the latest of: (1							
	three months beyond the filing date of a national application (other than CPA); (2) three							
	months beyond the date of entry of the national stage as set forth in §1.491 in an							
	international application; (3) the mailing of a first Office Action on the merits; (4) the							
	mailing of a first Office Action after the filing of a request for continued examination							
	under §1.114; or (5) after the filing of a request for a continued prosecution application but before the mailing date of the earlier of a final office action under §1.113, a notice							
	allowance under §1.311 or an action that otherwise closes prosecution in the application							
	then:							
	(1)	a certification as specified in §1.97(e) is provided below; or						
	(2)	a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or						
		included with the payment of other papers filed together with this						
		statement						

Application No. 09/90807009/908070 Page 3	Supplemental Information Disclosure Statement Attorney Docket No S63.2-9826-US01.
S63.2B-9826-US01 III. 37 C.F.R. $\S1.97(d)$. If this statem	ent is being filed after the mailing date of the
	1.113, a notice of allowance under §1.311, or an
	on in the application, but before payment of the
issue fee, then:	
	fied in §1.97(e) is completed below; and
	forth in §1.17(p) is authorized below, enclosed, or
included with payment	t of other papers filed together with this statement.
X IV. Fee Authorization. If any fee is d	ue for consideration of this Information Disclosure
Statement and full payment has not be	een submitted herewith, regardless of which boxes
have been checked above, the Comm	issioner is hereby authorized to charge any
additional fees associated with this co	ommunication to Deposit Account No. 22-0350.
The Commissioner is hereby authorize	ed to credit any overpayment associated with this
communication to Deposit Account N	To. 22-0350.
If paragraph II.1 or III is checked, also che	ck one of the paragraphs below
I hereby certify, under 37 CFR §1.97	(e)(1), that each item of information contained in
this Information Disclosure Statemen	t was first cited in a communication from a foreign
patent office in a counterpart foreign	application not more than three months prior to the
date of the filing of this information of	disclosure statement.
This communication v	vas not received by any individual designated in §
1.56(c) more than thirty days prior to	the filing of the Information Disclosure Statement.
I hereby certify, under 37 CFR §1.97	(e)(2), that no item of information contained in the
information disclosure statement was	cited in a communication from a foreign patent
office in a counterpart foreign applica	ation, and to the knowledge of the person signing the
statement after making reasonable in	quiry, no item of information contained in the
information disclosure statement was	known to any individual designated in 1.56(c) more
than three months prior to the filing of	of the Information Disclosure Statement.
For the purpose of this certification, Applica	nt considers the PCT International Search Authority
to constitute a foreign patent office.	

Application No. 09/90807009/908070
Page 4

Supplemental Information Disclosure Statement Attorney Docket No S63.2-9826-US01.

S63.2B-9826-US01

If this Information Disclosure Statement has been submitted without the appropriate box checked, Applicant requests that this Information Disclosure Statement be considered nevertheless if it is timely submitted under any of the provisions of 37 C.F.R. §1.97 or otherwise. Finally, if any petition is necessary to ensure consideration of this Information Disclosure Statement, Applicant requests that this be treated as such a petition.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Registration No. 43071

Date: September 2, 2003

6109 Blue Circle Drive, Suite 2000 Minnetonka, MN 55343-9185 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

f:\wpwork\lr1\09826us01_ids_20030902.doc

LIST	OF PAT	TENTS AND PUBLICATIONS		ATTY US01	DOCKET NO.: S63.2B-9826-	APPLICATI	ON NO.: 09/908070		
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				<u> </u>	ICANT: Dachuan Yang, Liquang Ta	g and Dixie Lang			
(Use several sheets if necessary)					G DATE: July 18, 2001	GROUP: 17	GROUP: 1762		
REFE	RENC	E DESIGNATION		U.S.	. PATENT AND PUBLISHED	APPLICATIO	N DOCUMENTS		
EXAM'S INIT.	S DOCUMENT NUMBER		D	ATE	NAME	CLASS/ SUBCLASS	FILING DATE IF APPROPRIATE		
	AA	5807605	9.	/15/98	Tingey et al	427/8			
	AB								
	AC						,		
	AD								
	AE								
	AF		<u> </u>						
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								
	FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER		ATE	COUNTRY				
	BA				,				
	BB		<u> </u>						
	BC		<u> </u>						
	BD		<u> </u>						
	BE								
	,	OTHER ART (I	ncl	uding A	uthor, Title, Date, Pertinent Pa	ges, Ect.)			
	CA								
	СВ								
	СС								
EXAMINER			Ī	DATE CONSIDERED					
EXAMINI not in con-	ER: In	itial if reference considered, whose and not considered. Include	ethe	er or not	citation is in conformance with A	IPEP 609; Drav	v line through citation if		